<DOC>
	<DOCNO>NCT01260129</DOCNO>
	<brief_summary>Korea newly adopt 8mg Silodosin daily . Against backdrops , clinical study design demonstrate newly adopt dose inferior exist dose efficacy safety .</brief_summary>
	<brief_title>Safety Efficacy QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive BPH</brief_title>
	<detailed_description>Silodosin highly selective α1A-adrenoceptor antagonist treatment sign symptom BPH . 4mg Silodosin twice daily approve Asia include Japan Korea . In US , 8mg Silodosin daily FDA approval already available . Korea newly adopt 8mg Silodosin daily . Against backdrops , clinical study design demonstrate newly adopt dose inferior exist dose efficacy safety . The study use double-blind , random assignment Korean men sign symptom BPH 12 week .</detailed_description>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Silodosin</mesh_term>
	<criteria>Patients diagnose BPH digital rectal exam ultrasonographic finding meet follow criterion . Outpatients age 50 Patients total IPSS score 8 high QoL score 3 high Patients prostate volume measure transabdominal ultrasonography , TRUS 20 ml great Patients maximum urinary flow rate ( Qmax_ ) 15ml/sec ( whose void urinary volume 120ml great ) Patients residual urinary volume 200ml great Patients history prostatectomy Patients history intrapelvic radiation therapy Patients history prostatic hyperthermia Patients prostate cancer suspect prostate cancer Patients complication consider likely affect urinary passing neurogenic bladder , bladder calculus active urinary tract infection . UTI Patients conduct selfcatheterization Patients renal impairment ( serum creatinine 3.0 mg/dl great ) Patients severe heptic disorder ( hepatic insufficiency , cirrhosis , jaundice , hepatoma ) total bilirubin 3.0mg/dL great AST/ALT 2.5 time higher normal level Patients history severe arrhythmia , cardiac failure , cardiac infarction , unstable angina , cerebral infarction within 6 month Patients history allergy αblockers Patients orthostatic hypotension around screen visit Patients experience investigational product treatment within 4 week form screen visit . Patients PSA 10 , Patients tumor identify prostate biopsy PSA 4 ( For patient take 5αreductase inhibitor 3 month presume double actual PSA level . ) Patients take unstable dos antidepressant within 3 month expect take unstable dos study Patients take alpha blocker within 2 week start therapy Patients take unstable dos 5αreductase inhibitor within 3 month start therapy expect take unstable dos study . Patients disqualify investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>BPH</keyword>
	<keyword>silodosin</keyword>
</DOC>